We are very happy to share our new pre-print* (medrxiv.org/cgi/content/sh…) where we compare SARS-CoV-2 IgG Ab prevalence over the months of Feb to Aug in the Brazilian cities of São Paulo and Manaus. @FAPESP Medical Research Council @ItauUnibanco #TodosPelaSaúde * not yet peer-reviewed

In our new paper (doi.org/10.1371/journa…) we focus on the natural history of chronic Chagas disease. Measuring Ab over ~12yr in untreated T-cruzi sero+ blood donors, we link spontaneously falling Ab level to less frequent cardiac damage and parasitaemia Ester C Sabino

Great paper highlighting the importance of spectrum bias in SARS-CoV-2 serology validation studies. bmj.com/content/371/bm…

Instituto Nacional de Salud🇨🇴 presentó recientemente los resultados preliminares del #EstudioDeSeroprevalenciaCol #EstudioPaís. El #ReportePreliminarNo1 incluye las tres primeras ciudades del estudio: Leticia, Barranquilla y Medellín. Abrimos (hilo) 🧶

Here is a thread to accompany our work published today in Science Magazine (science.sciencemag.org/content/early/…), comparing SARS-CoV-2 IgG antibody prevalence in Manaus and São Paulo. FAPESP Medical Research Council Itau Unibanco #TodosPelaSaúde

Our new study (preprint) looking at the "Social and racial inequalities in COVID-19 risk of hospitalisation and death across São Paulo state, Brazil" medrxiv.org/content/10.110… Another paper from the CADDE Project , co-led by Sabrina Li , Carlos Prete and I.

Clinical features and natural history of the first 2073 suspected COVID-19 cases in the Corona São Caetano primary care program: a prospective cohort study BMJ_Open bmjopen.bmj.com/content/11/1/e…

*Increasing frequency of the new P.1. lineage in Manaus* Preliminary results for the frequency of P.1 lineage in Manaus: 0% between March-Nov 2020, 52.2% in Dec 2020, 85.4% in Jan 2021 virological.org/t/genomic-char…

Why are we seeing a resurgence of COVID-19 in Manaus? thelancet.com/journals/lance…

CADDE preprint. A SARS-CoV-2 lineage of concern is growing rapidly in Manaus and across Brazil. Using a combination of genomic and epidemiological data, we characterise the emergence and altered characteristics of this new variant, P.1. Here is a short thread of our findings. 1/8

A more comprehensive way to compare results from different Chagas studies pubmed.ncbi.nlm.nih.gov/33909845/

Our preprint about reinfection by the P.1 SARS-CoV-2 lineage in repeat blood donors in Manaus is now out [not peer-reviewed] 🧪🦠🥼🌎 ▶️Check it out at: medrxiv.org/content/10.110…. ▶️Short thread on key findings🧵 1/10

“Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study” - seroprevalence of 70% (95% CI 67–73) by July 2020 in the largest Peruvian city in the Amazon rainforest: thelancet.com/journals/langl…

UPDATE #COVID19 Report 46: Brazil ➡️Healthcare pressure and inequities in healthcare capacity across Brazil drive high number of COVID-19 deaths ➡️ Half of Brazil’s COVID-19 deaths in-hospitals could have been avoided 👇Report 46 imperial.ac.uk/mrc-global-inf…

Better data is needed for tackling Chagas disease, a neglected heart disease! Presented in the #AHA21: abstractsonline.com/pp8/#!/9349/pr…. Full paper in the last Circulation issue: ow.ly/yTuK50Gg7S1. LewisBuss @medicinaufmg SIAC SBC Científico World Heart Federation Drugs for Neglected Diseases initiative Sergio Sosa-Estani

Chagas cardiomyopathy is not a problem only for young adults. See Bruno Brito´s study just published at: doi.org/10.1371/journa…. Elsayed Z. Soliman Ester C Sabino World Heart Federation Coalición Chagas @waldutra FAPEMIG Faculdade de Medicina da UFMG Adrian Baranchuk MD FACC FRCPC FCCS FSIAC

This new Practice article discusses what to do when patients ask: "Can I have blood tests to check everything is alright?" bmj.com/content/382/bm…